Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCovenant Asset Management, LLC
Latest Disclosed Ownership12,081 shares
Latest Disclosed Value $ 5,394,650
Covenant Asset Management, LLC reports 1.61% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 14, 2026 - Covenant Asset Management, LLC filed a 13F-HR form disclosing ownership of 12,081 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $5,394,650 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 30, 2026 disclosing 11,889 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 1.61% during the quarter. The current value of the position is $5,398,153 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-14 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,081 192 1.61 5,395 0.09 0.8122
2026-01-30 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,889 -215 -1.78 5,390 13.69 0.6384
2025-10-30 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,104 -51 -0.42 4,740 -12.40 0.5358
2025-07-17 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,155 -387 -3.09 5,411 -11.00 0.7998
2025-05-05 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,542 -85 -0.67 6,081 19.59 1.3392
2025-01-30 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,627 -137 -1.07 5,085 -14.35 0.7804
2024-11-12 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,764 118 0.93 5,936 0.15 0.9334
2024-08-02 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 12,646 553 4.57 5,927 17.27 0.9429
2024-04-23 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,093 799 7.07 5,055 9.99 0.8292
2024-01-22 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,294 252 2.28 4,595 19.69 0.8256
2023-10-31 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,042 -9 -0.08 3,840 -1.26 1.0123
2023-07-12 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,051 -19 -0.17 3,889 11.50 0.9867
2023-04-27 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,070 403 3.78 3,488 13.21 0.8299
2023-01-24 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,667 79 0.75 3,080 0.46 0.7354
2022-11-03 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,588 -92 -0.86 3,066 1.86 0.8741
2022-07-21 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,680 10,680 3,010 0.9561
2021-07-21 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,000 -100.00 0 -100.00
2021-04-19 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,000 -17,074 -94.47 215 -94.97 0.0670
2021-01-28 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,074 306 1.72 4,272 -11.64 1.4075
2020-10-29 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,768 -173 -0.96 4,835 -7.16 1.5494
2020-07-24 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,941 -326 -1.78 5,208 19.81 1.1526
2020-04-22 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,267 -81 -0.44 4,347 8.22 1.3112
2020-01-24 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,348 -520 -2.76 4,017 25.65 1.7581
2019-10-18 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,868 446 2.42 3,197 -5.36 1.6051
2019-07-17 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,422 307 1.69 3,378 1.38 1.7518
2019-04-26 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,115 66 0.37 3,332 -4.23 1.7506
2019-01-08 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,049 0 0.00 3,479 0.00 1.7528
2018-10-09 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,049 -486 -2.62 3,479 10.44 1.7527
2018-07-12 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 18,535 1,449 8.48 3,150 13.11 1.7019
2018-05-04 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 17,086 17,086 2,785 1.6093
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.